Brend

I have many reasons to live C:

[Andres Meraz-Brenez @iandresmeraz]

ASCENT-03 biomarker analysis at #ASCO26: sacituzumab govitecan showed longer PFS vs chemotherapy in previously untreated advanced TNBC patients who were not candidates for PD-(L)1 inhibitors.

The benefit was observed across Trop-2 expression levels, tBRCA wild-type and mutated tumors, and HER2 IHC 0/HER2-low subgroups.

These exploratory data reinforce SG as an active 1L option in this population, with no clear biomarker-defined subgroup limiting benefit so far.

#TNBC #MBC

[Andres Meraz-Brenez @iandresmeraz]

evERA BC at #ASCO26, presented by @jhaveri_komal, adds to a key question in ER+/HER2-negative advanced breast cancer: how should ESR1 testing guide sequencing when oral SERD combinations may benefit patients beyond ESR1-mutant disease? 🧬

Giredestrant + everolimus prolonged PFS2 and chemotherapy-free survival vs SOC endocrine therapy + everolimus, with a favorable interim OS trend. 📈

My takeaway: keep testing. ESR1 status still helps interpret benefit and guide sequencing among multiple post-CDK4/6i options. But SERD combinations should not be viewed as ESR1-only strategies.

[Andres Meraz-Brenez @iandresmeraz]

Urothelial cancer is moving fast at #ASCO26.

A few takeaways from the Highlights session: EV/pembrolizumab has reshaped 1L metastatic disease, ADC resistance is the next major challenge, and ADC combinations are rapidly moving into perioperative MIBC.

#GUOnc #BladderCancer

[Maite Bourlon @BourlonMaite]

Starting today!!! #IPCS2026 & #APCCC2026

Check the wonderful agenda ✅
https://t.co/KyTD89ajSz in person and online📤

Great faculty @Silke_Gillessen @Ecastromarcos @DrYukselUrun @tompowles1 @EAntonarakis @oncodaily @OncoAlert @urotoday

[Brend @Bren_JF]

@ArisMorales22 Tampoco me deja envíarte mensaje

[Brend @Bren_JF]

@ArisMorales22 Me interesa

[Brend @Bren_JF]

@AmericaMtzMtzz No me deja envíarte mensaje, como me contacto contigo??

[Brend @Bren_JF]

@Sodidkxo A mi tampoco me deja mandar mensaje

[Brend @Bren_JF]

@Mercadolfn4 Hola me interesa

[Brend @Bren_JF]

@Sodidkxo Hola me interesa también

[Brend @Bren_JF]

@doritamarin Me interesa, aún esta disponible?

[Maite Bourlon @BourlonMaite]

Great news for #bladdercancer & #globaloncology
@NCCN now provides Framework for Resource Stratification
https://t.co/D3VdjwhjUW

Great to be part of international reviewers included in this initiative 🇲🇽🇮🇳 @INCMNSZ_Uronco @TomFlaigMD @SpiessPhilippe @oncodaily @INCMNSZ_DirInv

[Maite Bourlon @BourlonMaite]

DAY3⃣ @asco #GU26 #kidneycancer The BELZUTIFAN story!

🔴LITESPARK-011 Belzu + lenva vs cabo for aRCC after PDL1
🔵LITESPARK-022 Adjuvant pembro+belzu vs pembro in localized ccRCC @DrChoueiri
🟠LITESPARK-024 dose escalation of belzu + palbo

#ASCOVoices @OncoAlert @oncodaily

[Maite Bourlon @BourlonMaite]

DAY 1 #prostatecancer news this PM @ASCO #GU26

🛑 PEACE 2: ADT+ RT +/- cabazitaxel in very high-risk localized PCa
📈 P1 escalation studies: VIR-5500 (AMX-500) a dual T-cell engager targeting PSMA & actinium-225-PSMA in mCRPC
🎉 PSMAddition: QOL w Lu-PSMA-617 mHSPC

@OncoAlert

[Maite Bourlon @BourlonMaite]

Get to know the #ascovoices #GU25 @ASCO @ConquerCancerFd

Follow our experts 📲💻🧑🏼‍⚕️👨🏻‍⚕️👩🏻‍⚕️

They will be summarizing the most important updates in GU Oncology ✅‼️

@OncLive @OncoAlert @UrologyTimes
@bergsa83 @OncBrothers @urotoday @Uromigos @oncodaily @PaolaVS94 @BourlonMaite

[Maite Bourlon @BourlonMaite]

@incmnszmx we were happy to receive @PBarataMD to discuss about #ProstateCancer 👨🏻‍⚕️👩🏻‍⚕️🌍🇲🇽

Multidisciplinary discussion w Urology, Genetics and pathology 📘🖇️🗂️💙

@JoseLuisROli @sof_mb @Elias31222749

[Los Uromigos @LosUromigos]

@GU25 TALPRO-2 SG final @neerajaiims
mSG 45.8 vs. 37.0 meses (HR: 0.796 P=0.0155)
✅ HRR-deficiente: HR: 0.549 (P=0.0035)
❌ HRR–no-deficiente/desconocido: HR: 0.878 (P=0.218)
❓ no-HRR detectado HR: 0.782 (P=0.1008)
@TDorffOnc Genética importa: ⬆️ efecto HRR+
Población ⬇️ fq

[Dirección de Investigación INCMNSZ @INCMNSZ_DirInv]

Estudio que muestra desconexión lo recomendado en el tx oncologico costoso con beneficios marginales y la práctica clínica cotidiana. DOI. 10.1158/1055-9965.EPI-24-0906, participación del @INCMNSZ, Alejandro Aranda Gutiérrez y cols.

[Dirección de Investigación INCMNSZ @INCMNSZ_DirInv]

Estudio que ilustra la necesidad de realizar pruebas de panel multigénico para la evaluación del riesgo de cáncer genético en mexicanos con con cáncer de páncreas exocrino. Doi: 10.1016/j.pan.2024.09.018, participación del @incmnszmx José Luis Rodríguez Olivares y cols.

[𝒻. @300moods]

Galaxy cake